ASENT is pleased to welcome our newest cohort of ASENT Board Members. Below you will find bios and headshots to share some of the outstanding work this group of individuals continues to do in the field of Neurotherapeutics.
Sharon Tamir, Head of GBM and Rare Oncology Indications
Sharon Tamir is the Head of GBM and Rare Oncology Indications at Karyopharm, where she is focused on the development of Selinexor, also known as KPT-330, selective inhibitor of nuclear export compound, for the treatment of patients with Glioblastoma and other rare oncology indications. Previously, she was the Head of External Alliances at United Neurosciences, and held the position of Head of Neurodegenerative and Infectious Diseases at Karyopharm Therapeutics, where she managed a portfolio of research projects. She led multiple successful grant submission
efforts to the National Institute of Health, Department of Defense and private foundations. Ms. Tamir built the neurodegenerative disease program at Karyopharm Therapeutics from hypothesis to clinical trial, resulting in a lucrative agreement for Biogen to acquire the program. Ms. Tamir received her B.A. in psychology from the Open University of Israel and her Heilpraktiker Diploma from The Trade school of Naturopathy Practitioners Saarbrucken, Germany. She is the co-Chair of the ASENT Annual Meeting Program Committee.
Dietrich Haubenberger, MD
Dietrich Haubenberger received his medical degree and training as a neurologist at the Medical University of Vienna, Austria, followed by a tenure track position to become Associate Professor of Neurology in 2014. Dr. Haubenberger’s research focuses on the area of movement disorders, where he is an expert in tremor disorders. He published in the field of clinical genetics, neurophysiology, outcome measures research, as well as clinical trials. From 2008-2011, Dr. Haubenberger completed a clinical research fellowship at the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health conducting
IND-regulated clinical trials in patients with Essential Tremor. Dr. Haubenberger returned to NINDS in 2014 as Assistant Clinical Director for Clinical Research, and built up and directed the NINDS Clinical Trials Unit. In 2019, Dr. Haubenberger transitioned into a role as Medical Director for Early Clinical Development at Neurocrine Biosciences. He is a member of the ASENT Annual Meeting Program Committee.
Aditya Joshi, MD
Dr. Aditya Joshi earned his MD at the University of Pittsburgh School of Medicine, after receiving an S.B. in Brain and Cognitive Science and an S.B. in Physics from the Massachusetts Institute of Technology. He completed residency in neurology, fellowship in epilepsy, and fellowship in clinical neurophysiology (focusing on intraoperative monitoring) at Stanford Hospital and Clinics, and is now an Assistant Professor of Clinical Neurology at the University of Pennsylvania. While at Stanford, Dr. Joshi participated in the Stanford Biodesign Innovation course, and was a member of the first Short Course in Adaptive Neurotechnologies held by the NIH-funded National Center for Adaptive Neurotechnologies. He is currently a member of the ASENT Annual Meeting Program Committee. He is very interested in the application of medical devices that utilize electromagnetic fields to interact with the body for the diagnosis and treatment of medically refractory epilepsy and other neurological disorders.
Danilo Vitorovic, MD
University of Vermont